Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

Journal: Nature Medicine

Published: 2018-09-26

DOI: 10.1038/s41591-018-0186-4

Affiliations: 19

Authors: 33

Go to article
Institutions FC
Laboratory of Molecular Immunology, The Rockefeller University, United States of America (USA) 0.45
Innere Medizin I - Onkologie, Hämatologie, Klinische Infektiologie, Klinische Immunologie, Hämostaseologie, Internistische Intensivmedizin, Germany 0.10
Duke Human Vaccine Institute (DHVI), United States of America (USA) 0.07
DZIF Partner Site Bonn-Cologne, Germany 0.07
Institute of Virology, UoC, Germany 0.04
Laboratory of Experimental Immunology, UoC, Germany 0.04
Department of Computer Science, Uni Tübingen, Germany 0.04
Praxis Hohenstaufenring, Germany 0.03
Division of Infectious Diseases, Cornell University, United States of America (USA) 0.03
Center for Virology and Vaccine Research, BIDMC, United States of America (USA) 0.03
Center for Molecular Medicine Cologne (CMMC), UoC, Germany 0.03
Praxis am Ebertplatz, Germany 0.02
The Rockefeller University, United States of America (USA) 0.02
Faculty of Medicine, Uni Tübingen, Germany 0.01
DZIF Partner Site Tübingen, Germany 0.01
Max Planck Institute for Informatics (MPI-INF), Germany 0.01
Duke Department of Surgery, United States of America (USA) 0.01
Duke Department of Immunology, United States of America (USA) 0.01
Duke Department of Molecular Genetics and Microbiology, United States of America (USA) 0.01

Return